MONDAY, AUGUST 21, 2017

Small antibodies suggest vulnerability in parasites that cause diseases

Scientists from Whitehead Institute have found a potential target for drugs that could stop parasites from entering host cells thanks to an enzyme that is important to the parasite’s infectious behavior, especially for malaria and toxoplasmosis. Read More »

Cell phone data to monitor spread of infectious diseases

Vast datasets from tracking mobile phone data could allow health professionals to track the infectious diseases that spread each season. Read More »

Visterra medication proves effective against influenza strains

Visterra Inc., a clinical-stage biotechnology company, recently published data that shows the effectiveness of its VIS410 in protecting people from both seasonal and potentially pandemic influenza strains. Read More »

New England Journal of Medicine reports on PMO-based therapeutic

On Wednesday, the New England Journal of Medicine published clinical data for AVI-7288, a PMO-plus antisense oligonucleotide, demonstrating the drug's safety. Read More »

New Visterra antibody broadly neutralizes dengue virus in studies

Visterra Inc., a clinical-stage biotechnology company, recently announced that its novel antibody known as VIS513 has shown positive results in its preclinical studies, where the antibody broadly neutralized all four dengue virus serotypes. Read More »

New study shows U.S. hospitalizations for adults with pneumonia

The Centers for Disease Control and Prevention (CDC) recently published a study detailing the cause of pneumonia hospitalizations for adults in the U.S. Read More »

Robin David Isaacs new chief medical officer at Entasis Therapeutics

Entasis Therapeutics, a company that uses its expertise and unique pathogen-targeted approach for creating and advancing new antibacterials, recently announced that it has made Robin David Isaacs, M.D., its new chief medical officer. Read More »

Vaccine products in R&D triples over last 10 years

The Tufts Center for the Study of Drug Development recently conducted a study, which showed that in the past 10 years vaccine products within the research and development pipeline have more than tripled. Read More »

Harvard team identifies protien required for viral replication

Harvard Medical School (HMS) said Thursday that researchers recently identified the vesicular stomatitis virus (VSV) protein structure that the virus needs in order to multiply and take over the body. Read More »

Studies explore drug-resistant antibiotics

Researchers are conducting studies to further understand and develop antibiotics to fight against drug-resistant illnesses. Read More »

TB can hide in bone marrow stem cells

A recent study conducted by the Forsyth Institute has shown that latent Tuberculosis (TB) bacteria uses the low oxygen (hypoxia) niches in bone marrow stem cells to hide from the immune system. Read More »

Second measles case of 2015 confirmed in Massachusetts

The Massachusetts Department of Public Health (MDPH) recently confirmed the second measles case in Massachusetts for 2015. Read More »

Synthetic vaccine particles may be crucial to mucosal vaccine research

Selecta Biosciences Inc., a clinical stage biotechnology company that is developing an innovative class of targeted antigen-specific immune therapies with synthetic vaccine particles (SVPs), recently announced that SVP may be crucial to developing an innovative vaccine technology targeting mucosal tissues. Read More »

C. Evan Ballantyne takes over as chief financial officer at Agenus

Agenus, Inc., an immunology company that creates novel treatments for cancers and similar diseases, said Wednesday that C. Evan Ballantyne will be its new chief financial officer.Ballantyne has over 30 years of experience with financial and operational work. Read More »

Researchers begin Phase II trial for diabetes reversing vaccine

Researchers from the Massachusetts General Hospital recently received approval from the U.S. Food and Drug Administration (FDA) to begin a Phase II clinical trial to test a generic vaccine’s ability to reverse advanced Type 1 diabetes. Read More »

MIT investigates better methods for preventing and responding to flu outbreaks

Researchers from MIT recently published a paper that evaluates the best methods of reducing the likelihood of contracting the flu by regularly using non-pharmaceutical interventions (NPIs) and effectively deploying the vaccine. Read More »

VBI provides update on hepatitis C vaccine research at conference

VBI Vaccines recently presented the latest data about its eVLP platform being used in creating a new hepatitis C vaccine candidate at the World Vaccine Congress Asia, held Wednesday and Thursday at the Suntec Singapore Convention & Exhibition Centre in Singapore. Read More »

Visterra collaborates with A*STAR to make monoclonal antibody for dengue

Visterra Inc., a clinical-stage biotechnology company with a unique technology platform to discover disease targets and create novel treatments for infectious diseases, and the Agency for Science, Technology and Research’s (A*STAR) Drug Discovery and Development (D3) unit, recently partnered to create VIS513 -- Visterra’s treatment that uses broadly neutralizing antibodies to fight dengue fever. Read More »

Microfluidic cell-squeezing tool shows promise for cell-based vaccines

Massachusetts Institute of Technology researchers recently demonstrated a microfluidic cell-squeezing device that introduces antigens to the body’s immune system’s B cells, a tool that may open a new approach to creating and implementing cell-based, antigen-presenting vaccines. Read More »

VBI Vaccines to present at Modern Vaccines Adjuvants & Delivery Systems Conference

VBI Vaccines will make a presentation titled “Optimization of the Process for Making Clinical Supplies of an Enveloped Virus-like Particle for Cytomegalovirus (CMV)” Monday at the Modern Vaccines Adjuvants & Delivery Systems Conference. Read More »